NL-OMON44370撤回3 期
A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with Atherosclerotic cardiovascular disease (ASCVD) or ASCVD- risk equivalents and elevated low density lipoprotein cholesterol (LDL-C) - MDCO-PCS-17-08 (ORION-11)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male or female subjects >=18 years of age.
- •2. History of ASCVD (CHD, CVD or PAD; see APPENDIX A in the protocol) or ASCVD-risk equivalents (type 2 diabetes, familial hypercholesterolemia, and including subjects whose 10-year risk of a CV event assessed by Framingham Risk Score or equivalent has a target LDL-C of <100 mg/dL).
- •3. Serum LDL-C >=1.8 mmol/L (>=70 mg/dL) for ASCVD subjects or >=2.6 mmol/L (>=100 mg/dL) for ASCVD-risk equivalent subjects at screening.
- •4. Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.
- •5. Calculated glomerular filtration rate >30 mL/min by estimatedglomerular filtration rate (eGFR) using standardized clinical methodology.
- •6. Subjects on statins should be receiving a maximally tolerated dose. Maximum tolerated dose is defined as the maximum dose of statin that can be taken on a regular basis without intolerable adverse events. Intolerance to any dose of any statin must be documented as historical AEs attributed to the statin in question in the source documentation and on the Medical History page of the electronic case report form (eCRF) (APPENDIX B from the
- •7. Subjects not receiving statin must have documented evidence of intolerance to all doses of at least two different statins (see APPENDIX B from the protocol).
- •8. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for >=30 days before screening with no planned medication or dose change during study participation.
- •9. Subjects must be willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
排除标准
- •1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study.
- •2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
- •3. New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection fraction <30%.
- •4. Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation.
- •5. Major adverse cardiovascular event within 3 months prior to randomization.
- •6. Uncontrolled severe hypertension: systolic blood pressure >180mmHg or diastolic blood pressure >110 mmHg prior to randomization despite anti-hypertensive therapy.
- •7. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in ALT, aspartate aminotransferase (AST), >3x the ULN, or total bilirubin >2x ULN at screening confirmed by a repeat abnormal measurement at least 1 week apart.
- •8. Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 2 years.
- •9. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the three years prior to randomization.
- •10. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of highly effective contraception (failure rate less than 1% per year) (eg combined oral contraceptives,barrier methods, approved contraceptive implant, longterm injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:
- •a. Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) AND more than 55 years of age.
- •b. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
- •c. Women who are surgically sterilized at least 3 months prior to enrolment.
- •11. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
- •12. Known history of alcohol and/or drug abuse within the last 5 years.
- •13. Treatment with other investigational products or devices within 30 days or five half lives of the screening visit, whichever is longer.
- •14. Planned use of other investigational products or devices during the course of the study.
- •15. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
- •a. Subjects who are unable to communicate or to cooperate with the investigator.
- •b. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency).
- •c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study).
研究者
相似试验
进行中（未招募）
1 期
A study to look at the changes in the fatty deposits in the walls of the blood vessels of your heart and blood levels of your good” and bad” cholesterol and safety when MDCO-216 is taken in patients with a recent heart problem caused by a decreased blood flow to the heart.acute coronary syndromeEUCTR2015-000826-13-HUThe Medicines Company120
进行中（未招募）
1 期
A study to look at the changes in the fatty deposits in the walls of the blood vessels of your heart and blood levels of your good” and bad” cholesterol and safety when MDCO-216 is taken in patients with a recent heart problem caused by a decreased blood flow to the heart.acute coronary syndromeEUCTR2015-000826-13-NLThe Medicines Company120
进行中（未招募）
1 期
A study to evaluate the effect of ALN-PCSSC treatment on low-density lipoprotein cholesterol levelsMedDRA version: 20.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2015-003772-74-DEThe Medicines Company480
撤回
3 期
A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with Atherosclerotic cardiovascular disease (ASCVD) or ASCVD- risk equivalents and elevated low density lipoprotein cholesterol (LDL-C)elevated levels of cholesterol1008220610013317HypercholesterolemiaNL-OMON44477The Medicines Company30
进行中（未招募）
1 期
A study to evaluate the effect of ALN-PCSSC treatment on low-density lipoprotein cholesterol levelsHypercholesterolemiaEUCTR2015-003772-74-NLThe Medicines Company480